tolafentrine has been researched along with monocrotaline in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ermert, L; Ghofrani, HA; Grimminger, F; Kreisselmeier, KP; Pullamsetti, S; Samidurai, A; Schermuly, RT; Schudt, C; Seeger, W; Weissmann, N | 1 |
| Fuchs, B; Ghofrani, HA; Grimminger, F; Krick, S; Pullamsetti, S; Schermuly, RT; Schudt, C; Seeger, W; Weissmann, N; Yilmaz, H | 1 |
2 other study(ies) available for tolafentrine and monocrotaline
| Article | Year |
|---|---|
Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Gelatinases; Hemodynamics; Hypertension, Pulmonary; Hypertrophy; Hypertrophy, Right Ventricular; Iloprost; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Monocrotaline; Muscle, Smooth, Vascular; Naphthyridines; Oxygen; Phosphodiesterase Inhibitors; Pulmonary Artery; Pulmonary Gas Exchange; Pulmonary Heart Disease; Rats; Rats, Sprague-Dawley; Vasodilator Agents; Ventricular Remodeling | 2004 |
Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration.
Topics: Administration, Inhalation; Animals; Cell Movement; Dose-Response Relationship, Drug; Extracellular Matrix; Hypertension, Pulmonary; Male; Monocrotaline; Myocytes, Smooth Muscle; Naphthyridines; Rats | 2005 |